Organisation paid for research Program year 2025 Source: CMS Open Payments

Allergy Asthma Specialists PSC

Neither a doctor nor a teaching hospital

Research payments

$163,823

15 payments

Through program year 2025, Allergy Asthma Specialists PSC is reported as receiving $163,823 in research payments, across 15 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$17,505	3
2024	Research	$70,513	5
2023	Research	$67,248	5
2021	Research	$8,558	2

Breakdown

Who paid Research payments · program years 2021–2025

Novartis Pharmaceuticals Corporation $163,823 15 payments

Studies the money was for Research payments · program years 2021–2025

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (Lou064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (Csu) Patients Inadequately Controlled By H1-Antihistamines $35,674 3 payments
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies $30,433 2 payments
A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled by H1-antihistamines followed by an optional open-label extension for up to another 3 years and an optional safety long term treatment-free follow-up period for up to an additional 3 years $27,032 1 payment
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks $26,404 2 payments
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines $22,875 2 payments
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista $9,500 1 payment
A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled $4,892 1 payment
A 24-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Extension Study to Assess the Safety of Csj117, When Added to Existing Standard of Care Asthma Therapy in Patients ?18 Years of Age $3,500 1 payment
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal and Open-Label Extension Study Followed By Long-Term Open-Label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (Lou064) in Adult Chronic Spontaneous U $3,113 1 payment
A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study to Assess the Efficacy and Safety of Csj117, When Added to Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. $400 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.